Stock Market Today 25.02.2026
Supernus Pharmaceuticals reported Q4 earnings of $0.92 per share, beating the Zacks estimate of $0.28. Revenue rose to $211.57 million from $174.16 million a year earlier. The company has topped consensus estimates for four straight quarters. Shares are up 2% year-to-date, but the stock holds a Zacks Rank #5 (Strong Sell) due to negative earnings estimate revisions.
